Fibrinogen and coronary risk

被引:23
作者
Koenig W. [1 ]
机构
[1] Department of Internal Medicine II, Cardiology, University of Ulm Medical Center, D-89081, Ulm
关键词
Fibrinogen; Fibrinogen Level; Coronary Risk; Arterioscler Thromb Vasc Biol; Plasma Fibrinogen;
D O I
10.1007/s11886-999-0068-y
中图分类号
学科分类号
摘要
The notion that fibrinogen is strongly, consistently, and independently related to coronary risk has been widely accepted. The evidence is based on numerous prospective epidemiological studies and clinical observations. However, the reasons why fibrinogen is elevated in coronary disease and in atherosclerosis are only incompletely understood. All cells involved in the atherogenetic process are able to produce cytokines which induce an acute phase reaction. The potential pathophysiologic mechanisms by which elevated fibrinogen levels mediate coronary risk are manifold: It forms the substrate for thrombin and represents the final step in the coagulation cascade; it is essential for platelet aggregation; it modulates endothelial function; it promotes smooth muscle cell proliferation and migration; it interacts with the binding of plasminogen with its receptor; and finally it represents a major acute phase protein. Whether or not fibrinogen is causally involved in atherothrombogenesis still remains to be determined, and even though other unsolved issues await conclusive answers, fibrinogen has emerged as an important additional marker of coronary risk. Copyright © 1999 by Current Science Inc.
引用
收藏
页码:112 / 118
页数:6
相关论文
共 69 条
[1]  
Braunwald E., Shattuck Lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities, N Engl J Med, 337, pp. 1360-1369, (1997)
[2]  
Ross R., Arteriosclerosis - An inflammatory disease, N Engl J Med, 340, pp. 115-126, (1999)
[3]  
Danesh J., Collins R., Appleby P., Et al., Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease, J Am Med Assoc, 279, pp. 1477-1482, (1998)
[4]  
Ernst E., Koenig W., Fibrinogen and cardiovascular risk, Vascular Medicine, 2, pp. 115-125, (1997)
[5]  
Caen J.P., Dravet L., Montalescot G., Abstracts presented to the fourth international fibrinogen symposium. Fibrinogen & cardiovascular disease, Blood Coagul Fibrinolysis, SUPPL. 1, (1999)
[6]  
Woodward M., Lowe G.D.O., Rumley A., Et al., Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women, Eur Heart J, 19, pp. 55-62, (1998)
[7]  
Smith F.B., Lee A.J., Fowkes F.R.G., Et al., Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study, Arterioscler Thromb Vasc Biol, 17, pp. 3321-3325, (1997)
[8]  
Smith F.B., Rumley A., Lee A.J., Et al., Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants, Br J Haematol, 100, pp. 758-763, (1998)
[9]  
Koch M., Kutkuhn B., Grabensee B., Et al., Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: A prospective study in 412 subjects, Nephrol Dial Transplant, 12, pp. 2603-2611, (1997)
[10]  
Sweetnam P.M., Thomas H.F., Yarnell J.W.G., Et al., Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease, Eur Heart J, 17, pp. 1814-1820, (1996)